3PH Alliance built a real-world evidence ecosystem that uses clinical and physician insights to drive care and strategy, by:  
(i) Combining large-scale registries that enable evidence generation and quality improvement
(ii) Deploying AI-powered software to unlock and scale real-world procedural data
(iii) Embedding a co-creation model that brings physicians into every stage of the MedTech product lifecycle

Visit website.

4C Medical's AltaValve is a supra-annular transcatheter mitral valve replacement (TMVR) system. The AltaValve system is intended to streamline the procedure to replace degenerated mitral valves compared to current solutions. AltaValve will also expand the population of patients eligible for treatment to include those who have undergone previous valve repair operations. 

Visit website.

52North is a med-tech company spun out of the University of Cambridge, backed by the world's leading cancer charities, and a NATO DIANA innovator, on a mission to transform emergency care. Their patented AsterTM platform technology is the world’s first low-cost and fully portable method of rapidly measuring cells. Their products include Neutrocheck®: awarded breakthrough status by the UK Government, and built to enable remote diagnosis and triaging of cancer patients at risk of neutropenia.

Visit website.

Accure Medical is revolutionizing dermatology with the Accure Laser System, the first 1726nm platform to achieve both CE Mark certification and FDA clearance for the long-term treatment of mild to severe inflammatory acne vulgaris. Leveraging its patented treat-to-temperature technology, the system ensures consistent, safe, and effective results for all skin types. With rapid adoption across the US, Europe, Asia, and the Middle East, Accure is addressing a significant global need with its groundbreaking solution for acne treatment.

Visit website.

Aces Diagnostics is a start-up company that was founded to develop and commercialize LymeSeek, a clinically accurate diagnostic test for Lyme disease. LymeSeek leverages machine learning for multiplex immunoassay interpretation and provides an actionable test result to providers in less than 24 hours. This breakthrough test not only promises to drastically improve patient outcomes but also stands to reduce the substantial financial burden of chronic care management associated with undiagnosed and untreated cases of Lyme disease.

Visit website.

Acorai is developing a non-invasive monitoring solution to measure pulmonary artery pressure. The handheld device utilizes a unique combination of acoustic, electrocardiographic, pressure, seismic and visual sensors to collect robust data to be analyzed using a machine learning engine to evaluate heart failure progression. The company's solution is an alternative to the current standard procedure, which involves right heart catheterization performed in a catheterization lab to evaluate heart functionality.

Visit website.

Adaptyx Biosciences, a Stanford University spin-off, is building a biomonitoring platform that leverages 15 years of research in molecular switches and microarray patches, enabling minimally-invasive real-time, continuous sensing of small molecules and proteins. Adaptyx's library of multi-analyte sensors will enable deeply personalized medicine across drug dosing, hormone regulation, kidney health, cardiovascular disease, and oncology.

Visit website.

AiM Medical Robotics is a Massachusetts-based neurosurgical robotics company commercializing a compact, MRI-compatible surgical robot that enables intra-operative imaging to account for brain shift and facilitate real-time monitoring of therapy delivery. AiM’s platform harnesses real-time MRI to ensure precise placement of neurostimulation leads for Parkinson’s patients and its versatile capabilities also support a wide range of neurosurgical procedures, including biopsies, tumor ablation, and intracranial therapeutic delivery with a >$10B market opportunity. Built on over 15 years of NIH-funded research totaling approximately $15 million, AiM’s proprietary and patented technology reflects the deep expertise of its founding team that completed an $8.1 million Series A financing round funding a first-in-human clinical trial at Brigham and Women’s Hospital in Boston.

Visit website.

Aliph Medical is developing AiOne, an all-in-one ophthalmic diagnostic platform powered by swept-source optical coherence tomography (OCT). AiOne provides higher imaging speed, resolution, and tissue penetration than traditional spectral-domain systems, enabling comprehensive visualization across a broad range of eye conditions. The system integrates AI-supported analysis to streamline clinical workflow and support more timely diagnostic decision-making. 

Visit website.

Altyx Medical is developing a suite of minimally invasive pelvic-floor technologies for high-prevalence female pelvic disorders. Its lead product, ODiSi™, is a device-based therapy designed to treat obstructed defecation syndrome (ODS), a common form of female constipation affecting approximately 18% of women and frequently associated with rectal prolapse. ODiSi™ has received FDA Breakthrough Device designation, completed first-in-human clinical studies with one-year outcomes demonstrating safety and efficacy, has been supported by National Science Foundation funding, and is preparing to advance into pivotal clinical trials.

Anaut is a Tokyo-based technology company that is passionate about using the power of AI to drive innovation in the healthcare industry. Our mission is to revolutionize surgery by developing AI precision mapping technology that can improve surgical outcomes and reduce the risk of complications. Our flagship product, Surgical Vision EUREKA, is a game-changing solution that has been specifically designed to support this mission. EUREKA uses cutting-edge algorithms and deep learning methodologies to achieve real-time precision mapping of the surgical field, allowing surgeons to navigate through complex anatomical structures with greater precision and accuracy. By leveraging the power of AI, we believe that we can transform the surgical landscape and provide better outcomes for patients around the world.

Visit website.

Bioheart develops minimally invasive catheter-based solutions for the cardiovascular market, based on two core technologies: thin-strut bioresorbable scaffolds (BRS) and renal denervation (RDN). The company’s Iberis Renal Denervation System is the only radiofrequency renal denervation system with a specially designed catheter for both transfemoral and transradial procedures.

Visit website.

Anuncia Medical develops noninvasive technologies for cerebrospinal fluid (CSF) management, focusing on reducing the need for repeat brain surgeries in patients with hydrocephalus. Its flagship product, the ReFlow™ Mini Flusher, is designed to restore or maintain CSF flow within shunt systems by allowing patients to flush blockages at home with a simple press of a soft dome implanted beneath the scalp. The device is FDA-cleared and has been successfully launched at leading neurosurgical centers across the United States.

Visit website.

28% of adults in the United States reported having chronic low back pain, yet current surgical treatments have unacceptably low success rates. Aposture Surgical has developed and clinically proven two radically different solutions to break this cycle of failure: an ultra-minimally invasive treatment for lumbar spinal stenosis and a novel fixation system for spinal fusion. Moreover, Aposture Surgical seeks to transform spinal surgery with its AI-enabled navigation system and robotic surgery platform to guide its surgical procedures.

Visit website.

AquaPass Medical has developed, Eccon, a noninvasive, drug-free system to remove excess fluid in patients with chronic heart failure, end-stage renal disease, and other causes of fluid overload. The wearable device induces controlled perspiration by circulating warm air across the skin, safely removing fluid through natural evaporation. 

Visit website.

Visit website.

Arsenal Medical develops innovative biomaterials to solve challenging and underserved medical problems. Our lead products target neurovascular and trauma conditions providing control of blood flow to tumors and bleeding conditions, such as hemorrhage. 

Visit website.

ART MEDICAL develops the smART+ Platform, a sensor-based feeding tube system that provides real-time management and personalized nutrition delivery for ICU patients. The platform continuously monitors tube position, detects reflux, and adjusts feeding to maintain optimal delivery, a workflow shown in clinical studies to reduce ICU length of stay and mechanical ventilation duration by more than three days. By enabling data-driven nutritional care and improving staff efficiency, smART+ supports safer, more consistent treatment for critically ill patients. The system is already in clinical use in Israel, Europe, and the UK, with FDA submission underway and approval anticipated in 2026.

Visit website.

The Atmo Gas Capsule is a unique ingestible capsule to provides unique insights into gut health and microbiome function. The device assesses the functional health of the GI system by means of measuring gaseous biomarkers as it passes through the GI system. Atmo Biosciences investigational device offers the potential to shed new light on disorders of the gut, beginning with highly prevalent motility disorders such as gastroparesis and slow transit constipation.

Visit website.

Aurenar’s V-Link product is the first single-use, non-invasive neuromodulation platform designed for intensive care units.  V-Link applies targeted vagal stimulation through a nerve branch in the ear to boost the body’s natural ability to reduce inflammation, the underlying cause of life-threatening and costly complications.  V-Link is uniquely designed to address specific needs for use in intensive care units and is backed by proof of both clinical and cost benefits from 3 randomized controlled clinical studies spanning hemorrhagic stroke, ischemic stroke, and glycemic control.

Visit website.

AutoMedicus Corporation has developed a transformative closed-loop blood pressure control device, called the AutoPress, for use in the OR and ICU. The AutoPress was recently designated as a Breakthrough device by the FDA (CDRH).

Visit website.

Autonomix (Nasdaq: AMIX) is a medical device company developing a minimally invasive nerve-sensing, ablation, and verification system to advance the diagnosis and treatment of diseases involving the nervous system. The company’s catheter-based microchip sensing array is designed to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies. This platform enables transvascular diagnosis and treatment of conditions affecting the peripheral nervous system. Initially focused on pancreatic cancer pain, Autonomix’s technology has potential applications across multiple fields, including cardiology, renal denervation, and chronic pain management.

Visit website.

Axena Health is dedicated to improving the lives of women with pelvic floor disorders. The company's Leva Pelvic Health system helps women train and strengthen their pelvic floor muscles from their homes to improve the management of stress, mixed, and mild-to-moderate urinary incontinence and chronic fecal incontinence. 

Visit website.

AyrFlo develops wearable respiratory monitoring solutions for early detection of breathing deterioration. Its flagship product, the SmartAyrpatch, is a self-adhesive sensor worn on the neck that continuously tracks breathing metrics and transmits actionable, patient-specific data to clinicians via proprietary software. The system enables real-time monitoring to support timely interventions and improve patient outcomes.

Visit website.

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life.

Visit website.

Biomed Simulation develops advanced simulation-based training solutions that combine medical device technology with patient-free immersive experiences. Their CALIFIA platform helps clinicians build proficiency in complex critical care and operating room environments, improving standard-of-care and reducing risk for patients and healthcare providers. Leveraging AR/VR/XR, haptics, and physiology-driven scenarios, Biomed Simulation enables realistic, evidence-based medical training across the care continuum. 

Visit website.

BioMEMS Diagnostics is developing a highly sensitive, handheld point-of-care diagnostics platform that delivers laboratory-grade results in under five minutes. The system combines a portable analyzer with disposable test cartridges and smart device integration, enabling rapid, quantitative biomarker detection directly from complex biofluids. Using proprietary microelectromechanical system (MEMS) technology, BioMEMS can measure analytes at concentrations as low as one part per trillion. 

Visit website.

Portable organ testing and preservation device with potential to eliminate the years-long waitlist for lifesaving kidney transplants. We recently received an FDA Breakthrough Device Designation based upon our compelling preclinical data vs. the standard of care.

Visit website.

BRIJ Medical develops advanced solutions for incision closure, wound support, and scar therapy. The company’s flagship product, the Brijjit® Force Modulating Tissue Bridge, has been clinically proven to reduce wound breakdown and scar formation by minimizing tension on healing tissues. Designed for efficiency, it enables faster closure compared to traditional sutures and offers a cost-effective option for surgeons, ambulatory surgery centers, and hospitals.

Visit website.

Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions.

Visit website.

CAPS Medical is developing a solution to treat a wide range of solid tumors using Non-thermal Atmospheric Plasma (NTAP). This minimally invasive procedure selectively destroys cancer cells without damaging the surrounding healthy tissue. Clinically tested ,working towards commercialization.

Visit website.

Cardiovascular Engineering develops breakthrough minimally invasive artificial heart technologies to transform treatment of heart failure. TwinHeart is our flagship fully implantable ventricular assist device, delivering partial cardiac support via catheter-based implantation under local anesthesia, promising rapid recovery, reduced costs, and improved quality of life for most of the advanced heart failure patients.

Visit website.

Thoraguard® is an FDA-cleared automated digital chest drainage system, proven in use with over 15,000 cardiothoracic surgery patients. Clinically validated at leading institutions including Stanford, NYU Langone, and Mayo Clinic, Thoraguard reduces length of stay and major complications such as post-operative atrial fibrillation, driving substantial cost savings for hospitals.

Visit website.

Cerevia Neurosciences is a full stack closed-loop neuromodulation platform that combines functional MRI, deep transcranial magnetic stimulation (TMS), with AI-driven personalization to treat dementia. Our mobile Ladybug™️ unit delivers safe, non-invasive, and scalable neuromodulation therapies—bringing precision brain health directly to patients and providers at memory care centers and assisted-living facilities. Backed by 50+ patents, we are building mobile, direct point-of-care closed-loop multi-TMS neuromodulation therapy aided with fMRI for dementia at scale.

Visit website.

Channel Robotics has developed an affordable, handheld robotic platform for flexible endoscopy that attaches to, & interfaces with existing endoscopes. The system—Channel ONE™ controller plus EC180™ single-use instrument—delivers AI-assisted motion control with steerable advance/withdraw for precise tissue manipulation, initially targeting GI endoscopic submucosal dissection (ESD).

Visit website.

Visit website.

CoMind is developing a noninvasive solution to transform the way the brain is monitored. The company provides a multidimensional view of brain activity using light. CoMind's mission is to change the way neuroscience and neurosurgery is conducted by expanding the amount of information available to clinicians to enhance the clinical management of neurological disorders.

Visit website.

The TriPair™ Technology is a novel minimally invasive tricuspid repair solution designed to treat Tricuspid Regurgitation —a condition that affects millions globally, with the vast majority currently remaining untreated. TriPair™ simplifies transcatheter repair through an innovative edge-to-spacer approach, aiming to reduce procedural complexity and improve access to care. TriPair™  is designed to be simple, fast (procedure time under 30 minutes), and highly effective, empowering physicians in both established and underserved markets to treat patients who cannot be helped with existing technologies. Following a successful first-in-human trial, TriPair™ is now being prepared for evaluation in global feasibility studies across multiple continents.

Visit website.

CoreDio is a non-invasive, catheter-quality intracardiac pressure and flow monitoring SaaS platform and algorithms that improves heart failure patient outcomes. Powered by its patented AI-guided Cardiac Performance Simulation Engine™ (CPSE), it uses routine checkup data, wearable sensors, and BP cuffs to estimate LVEDP, CVP, SVR, and CI, enabling early HF escalation detection, timely medication titration, and major readmission reductions. CoreDio targets a $6.3B market for HF management and remote patient monitoring.

Visit website.

CygnusMed is advancing endovascular care with a novel hemostatic valve designed to provide continuous, uninterrupted sealing of the guiding catheter during interventions. The device enables arterial blood pressure monitoring without the need for a second arterial line, minimizes blood loss, and supports continuous saline flushing of the catheter to significantly reduce the risk of iatrogenic emboli. By addressing critical challenges in endovascular procedures, CygnusMed's innovative solution enhances safety, efficiency, and patient outcomes.

Visit website.

DeepSight Technology develops advanced medical imaging solutions using proprietary sensing technology to enhance diagnostic ultrasound capabilities. The company’s NeedleVue Technology is designed to improve ultrasound-assisted needle guidance, addressing challenges such as complex calibration, reduced sensitivity, and angle dependence. By integrating innovative sensor technology with interventional devices, NeedleVue enables real-time verification of device placement, aiming to reduce procedural uncertainty and streamline interventional workflows. DeepSight Technology operates from the San Francisco Bay Area and Clayton, Missouri, with a focus on expanding the range and effectiveness of diagnostic ultrasound.

Visit website.

Description comings soon.

Visit website.

Echopoint Medical is developing a family of optical-fiber based sensors which integrate into microcatheters to guide and improve outcomes during interventional cardiology procedures. The company's iKor platform translates ultrasonic signals to measure blood pressure and flow to more accurately assess, diagnose and treat patients with coronary artery disease and coronary microvascular dysfunction.

Visit website.

Efemoral Medical is a clinical stage startup developing a next-generation drug-eluting bioresorbable scaffold for the treatment of PAD. Using a minimally invasive procedure, the Efemoral Vascular Scaffold System is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. The scaffold is strong enough to hold the vessel open, is flexible enough to accommodate the complex skeletal motion of the leg, and elutes a drug to prevent scarring inside the vessel which leads to the need for repeat procedures. The scaffold is naturally absorbed by the body over time, thus leaving behind no permanent implant.

Visit website.

Egg Medical develops and commercializes next-generation radiation protection systems designed to dramatically reduce scatter radiation exposure during x-ray–guided procedures. The company’s flagship product, the EggNest platform, provides comprehensive protection for all personnel in the procedure room while maintaining clinical workflow efficiency. By minimizing the need for heavy shielding aprons, Egg Medical’s technology enhances safety, comfort, and ergonomics for healthcare teams across a $6.8 billion global market.

Visit website.

CDX is a compact portable extracorporeal bypass pump for partial cardio-pulmonary support, adaptable to multiple circuit configurations including oxygenators. CDX's technology is an innovative, light-weight support system with multiple power options. The CDX pump platform is a disposable cartridge combined with a re-useable controller and stator. The entire system is less than 6 pounds in weight and can be primed and ready to support in less than 2 minutes.

visit website

enlightenVue™ has developed a novel single-use micro-endoscope platform with the industry’s smallest diameter (2mm) and two working channels, which can be used in a single procedure for both diagnostic and therapeutic interventions. The surgiVue™ platform’s dual functionality is based on a patented, expandable tip to provide access for multiple instruments along with superior imaging.

Visit website.

Epion Therapeutics is developing a minimally-invasive treatment that can bring early intervention to patients with corneal degeneration. Keratoconus is a common type of corneal ectasia that results in corneal thinning that progresses to the cornea taking on a conical shape that causes functional vision loss. Epion’s EpiSmart solution combines the delivery of a high concentration of riboflavin into the stroma with a UVA light device to optimize cross-linking and enhance therapeutic effectiveness. 

Visit website.

Field Orthopaedics is dedicated to developing innovative products to meet the needs of complex fracture management, arthritis and microsurgery. The company's portfolio of cannulated screws and intramedullary nailing system address the challenges critical to advancing hand surgery.

Visit website.

Flow Medical is developing a novel thrombolytic catheter for the treatment of pulmonary embolism. The device will combine imaging, infusion, and monitoring into a single solution to streamline procedures, improve therapeutic efficacy, and reduce inventory needs.

Visit website.

Fluid Biomed is a VC-backed pre-clinical medical device start-up that has developed the world’s first bio-resorbable stent to cure brain aneurysms. The company's innovative polymer technology allows physicians the versatility of treating a wider variety of aneurysms more safely and efficiently. 

Visit website.

FoxEyes Robotics develops advanced surgical robotic systems and automated components, combining precision engineering with Vision Tracking Technology and AI-driven data integration. Their solutions aim to enhance safety, usability, and efficiency in hard-tissue surgical procedures with significantly higher accuracy. 

Visit website.

Freyya Health is developing the first on-the-go pelvic floor monitoring and feedback device designed to address the root causes of pelvic floor disorders rather than just the symptoms. The Freyya™ device uses a tampon-like biosensor to monitor pelvic floor muscle activity, supporting more effective physical therapy. It can be used both while stationary and during moderate to vigorous exercise, enabling real-world monitoring and personalized feedback to improve outcomes for people with pelvic floor dysfunction.

Visit website.

FundamentalVR offers an Immersive VR platform for specialty suite procedures and is a strategic partner helping med-device leaders to solve the Competency at Scale Gap. Through its purpose-built immersive VR platform, FundamentalVR provides high-fidelity VR, including unique HapticVR capabilities, for the precision of specialty surgeries, as well as behavioral telemetry and assessment data for AI/ML-driven insights. 

Visit website.

GenesisTissue is developing regenerative breast tissue using advanced 3D bioprinting technology. The technology combines a bioprinted personalized breast scaffold with the patient’s own fat cells to create an engineered tissue solution that regenerates. By combining presurgical planning, plan-specific guidance, and personalized implant design, GenesisTissue aims to advance breakthroughs in tissue engineering for reconstructive and cosmetic breast indications, with potential for broader soft tissue applications.

GRIP Molecular Technologies has developed a novel CRISPR-based diagnostic that enables molecular testing in a simple lateral flow format for both point-of-care (POC) and point-of-need (PON) infectious disease testing. The platform delivers test results comparable to existing POC and lab-based molecular tests in under 15 minutes at room temperature, eliminating the need for specialized equipment or laboratory infrastructure. This breakthrough technology positions GRIP to address the growing demand for rapid, accurate, and accessible molecular diagnostics in diverse healthcare settings.

GT Medical's GammaTile Therapy is a targeted approach for delivering radiation to brain tumor cells. The company's technology minimizes complication while optimizes therapeutic efficacy. Placed by a neurosurgeon during resection, GammeTile's provide uniform radiation-source spacing to ensure even dose distribution. 

Visit website.

GuideAI Health automates the early detection of chronic vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts. The platform's first product addresses the 90% underdiagnosis/misdiagnosis rate of peripheral vascular disease in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision. 

Visit website.

Gyder Surgical's Gyder Hip System is a non-invasive, pin-less navigation solution for total hip replacement. The system is an open platform that can be used with a surgeon's preferred implant system, reduces radiation exposure by not requiring CT or X-ray imaging, and seamlessly integrates into existing workflows due to the system's simple set-up and quick calibration.

Visit website.

HelpWear is developing a revolutionary heart monitor that continuously records traditional medical-grade ECG signals while being discreetly worn on the upper-left arm. This breakthrough unlocks a $6B market opportunity by uniquely combining patient comfort with the precision of a clear, clinically accurate ECG signal. By enabling significantly extended wear time to document even the most elusive arrhythmias, our technology increases the detection of actionable cardiac events by 6x - empowering physicians to deliver more timely, personalized, and guideline-directed therapies to protect patients from serious, yet preventable, outcomes.

Visit website.

HemaSense has developed a wearable patient monitoring device which uses bioimpedance to detect the onset of bleeding beneath the surface of the skin before it is visible at skin level.  The initial target application is detecting access site bleeding complications following femoral access catheter based procedures. Access site bleeding complications occur in almost 10% of patients receiving a large bore femoral access catheter procedure.

Visit website.

Hy2Care's vision is to support patients in the fight against osteoarthritis. The company's lead product, CartRevive, is a hydrogel implant composed of dextran and hyaluronic acid conjugates that form a resorbable scaffold when injected. The hydrogel enables natural restoration of tissue defects by creating an environment conducive to cell regrowth that proceeds towards the restoration of smooth hyaline cartilage. 

Visit website.

iChor Vascular's goal is to become the 1st-line therapy for treating peripheral vascular occlusions. The company's ICHOR Panacea technology is a versatile, catheter-based solution that provides rapid reperfusion to occluded vessels, without the need for thrombolytic drug therapies or complex surgery. 

Visit website.

Illuminant Surgical is building a precision access and visualization platform, Skylight, that projects medical images directly on the patient. Skylight uses advanced sensors, computer vision, and noninvasive stickers to guide clinicians with millimeter level accuracy across a wide variety of indications such as spine surgery, pain management, and interventional radiology. 

Visit website.

Image Navigation Ltd. has developed IGI 2.0, a high-precision GPS for dental implant surgery, utilizing both navigation for accuracy and robotics for safety. In dental surgery, the handpiece and patient both move simultaneously, so real-time navigation is essential. IGI updates the onscreen position of the drill 50 times per second utilizing proprietary no-observable-lag tracking. This allows accurate visualization of the intrabony position of the handpiece, position, angle, and depth, providing the dentist with complete confidence that the procedure is executed according to plan.

Visit website.

Imaginostics is developing next-generation diagnostic solutions to support clinicians and drug developers. The company’s QUTE-CE MRI technology is a noninvasive quantitative imaging solution that enhances existing MRI machines with quantitative measuring capabilities to measure vascular function and structure. Imaginostics is actively utilizing its technology in pre-clinical and clinical research in the fields of cardiology, oncology and neuroscience.

Visit website.

Visit website.

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics.

Visit website.

Instrumentum provides outsourced surgical instrument sterilization by load-balancing onsite hospital systems and surgery center volume with offsite capacity.

Visit website.

Intrinsic Therapeutics is a commercial-stage medical device company dedicated to reducing reoperations for patients undergoing lumbar discectomy. The company's flagship product, Barricaid, is the only PMA-approved device designed to close annular defects following discectomy, the most commonly performed spine procedure. Barricaid has met safety and efficacy requirements, resulting in a dedicated C-Code for facility payment, a series of ICD-10 diagnostic codes, and a recently established Category 1 CPT code for physician reimbursement.

Visit website.

iO Urology aims to improve the lives of people living with urologic conditions. The company’s CarePath device is a remote patient monitoring system to promote urologic care at home. CarePath provides real-time, quantitative measurement of urinary output and flow to support the management of lower urinary tract symptoms from conditions such and benign prostatic hypertrophy and overactive bladder. 

Visit website.

JelikaLite is a clinical-stage medtech company developing innovative neuromodulation therapies for pediatric neurological disorders. Its lead product, Cognilum, is an FDA Breakthrough-designated wearable device designed to reduce symptoms of autism spectrum disorder (ASD). The Cognilum platform combines non-invasive brain stimulation with EEG-based AI personalization to improve language, responsiveness, and socialization in children with ASD.

Visit website.

Joint Preservation Innovations (JPI) is a regulatory stage orthopedic medical device company developing the Articulator™ platform of tools to enhance dexterity and surgical capability in arthroscopic, spinal and robotic musculoskeletal procedures.  Awarded an FDA Breakthrough Device Designation and numerous patents, JPI's mission is to transform minimally invasive surgery through technologies that enhance patient outcomes.  Most recently, the company submitted a 510(k) on its lead arthroscopic product, making a pivotal step towards commercialization.  

Visit website.

Juniper Biomedical is developing a precision neuromodulation micro-implant to treat pelvic health conditions.

Visit website.

Lean Medical Technologies is developing a novel implantable device for weight loss designed for placement through a simple outpatient or office-based procedure. The minimally invasive system is intended to provide an alternative to traditional bariatric surgery, aiming to reduce procedural risk, recovery time, and complication rates. The implant is designed to support effective, long-term weight reduction without the need for permanent anatomical alteration.

Visit website.

LEM Surgical is focused on creating and providing the next generation of robotic surgical systems. The company's flagship product, the Dynamis System, is a multi-arm robotic surgical system that incorporates novel navigation capabilities and has an open architecture for handling concentric tools. Dynamis is intended to be a platform technology for orthopedic and neurosurgical applications.

Visit website.

Lentek Surgical's is a pre-commercial company committed to the development of contrast-less medical devices for spine surgery.

Visit website.

LN Robotics is developing robotic systems and solutions to innovate percutaneous coronary intervention procedures. The platform provides precision, stability, and confidence to achieve better patient outcomes.

Visit website.

Macuject is a clinical decision support platform that integrates retinal imaging AI with real-time payer rules to optimise treatment selection for intravitreal injections for macular degeneration. By aligning clinical data, physician intent, and insurer constraints at the point of care, it enables earlier access to better therapies and greater revenue, simultaneously generating unique, unprecedented real-world insights for scalable Pharma analytics.

Visit website.

magAssist is a medical device company developing advanced solutions for heart failure treatment and circulatory support. Its portfolio includes an interventional artificial heart for PCI procedure protection, which has received U.S. FDA Breakthrough Device Designation, as well as a high-flow, long-duration extracorporeal magnetic levitation heart for acute cardiogenic shock and a magnetic levitation ECMO system. Through its innovations, magAssist is working to expand treatment options for patients with severe cardiac conditions.

Visit website.

MALCOVA’s Narrow-Beam CT reinvents CT’s workhorse role in radiology, eliminating the scatter, high dose, bulky size and resolution trade-offs that hamper conventional scanners. Its ultra-thin x-ray ribbon and line-detector architecture deliver MRI-grade 3-D clarity in seconds at routine screening dose. We’re first unleashing this power in breast-cancer and stroke imaging, where catching disease at its very earliest moment saves lives.

Visit website.

Nanochon’s Chondrograft™ is a synthetic, off-the-shelf implant designed to treat focal chondral and osteochondral knee defects in active patients. Made from a proprietary polymer blend and 3D-printed to mimic natural cartilage and bone architecture, it provides immediate mechanical support while promoting long-term tissue regeneration—bridging the gap between conservative care and total knee replacement.

Visit website.

nCight is transforming surgical intelligence by converting surgeon behavior into structured, actionable data. The company builds the foundational data infrastructure that connects healthcare providers with medical technology developers, enabling the aggregation and refinement of behavioral insights into high-quality datasets. By turning real-world surgical actions into analyzable intelligence, nCight empowers surgical robotics, AI developers, and industry partners to train smarter models and design more effective, scalable solutions for the operating room.

Visit website.

Percutaneous endovascular procedures are now among the most common, used for aneurysm repair, carotid artery stenting, stroke treatment, pulmonary embolism treatment, and heart valve replacement, among other applications. The most frequently used access points for arterial procedures are the femoral and radial arteries, as well as the femoral or jugular veins. Neurofine has developed a breakthrough neurovascular approach with a fully automated system for percutaneous access and closure of the carotid artery and veins, which reduces procedure time, radiation exposure for patients and medical staff, and related risks and costs. Preclinical and early clinical results in patients on blood thinners confirm the safety and efficacy of the Neurofine closure system. The current annual market size for vascular access and closure in the USA exceeds $1.5 billion.

Visit website.

New Phase Mission focuses on prolonging stage IV cancer patients’ lives while preserving the quality that makes life meaningful.
The technology combines magnetic nanoparticles containing which are delivered to the cancer tissues and are heated to 50°C using an Electromagnetic Induction Systems (EIS) which generates an Alternating Magnetic Field (AMF) and applies magnetic hyperthermia, causing destruction to the cancer cells since they are more sensitive to heat, leaving healthy cells unharmed, for the purpose on stabilize the disease and turn it to chronic managed condition.

Visit website.

Newronika's AlphaDBS is a closed-loop deep brain neuromodulation system. The device interprets the bioelectrical neuronal activity (local field potentials, LFPs) in the brain areas where stimulation is delivered and accordingly adapts moment-by-moment the stimulation to follow patient’s clinical condition. The technology is being developed as a treatment for Parkinson's disease.

Visit website.

Nitinotes develops the EndoZip™, the first fully automated endoscopic suturing system for Endoscopic Sleeve Gastroplasty (ESG), a minimally invasive weight-loss procedure. Designed for efficiency, EndoZip enables a single-operator ESG procedure with automated, standardized suturing, reducing variability, procedure time, and training requirements. The system facilitates outpatient treatment with low-risk and predictable outcomes, addressing the growing need for effective, non-surgical obesity interventions.

Visit website.

Noah Labs Vox eliminates the no. 1 cause of hospital admissions - congestive heart failure - 2 weeks before hospitalization by analyzing voice changes caused by fluid build-up in the lungs and vocal tract. Trained on the world's largest heart failure voice data set, the patented technology is being piloted at Mayo Clinic, UCSF and Charité Berlin. 

Visit website.

Novian Health has developed a laser-based system for the treatment of tumors. The technology is intended to be a minimally invasive alternative to surgery in select cancerous and non-cancerous tumors. Novian has received the CE Mark for the treatment of malignant and benign breast tumors. The company's Novilase technology is currently cleared in the US for the treatment of benign breast tumors and soft tissue ablation.

Visit website.

Noze is enabling early disease diagnostics through digital odor perception. The company is developing an advanced digital nose that is capable of accurately detecting and identifying odors in real-world settings. The company’s mission is to enable real-time disease detection at the point-of-care through the identification of breath-based odor biomarkers. 

Visit website.

Nutromics is pioneering Continuous Molecular Monitoring (CMM), a real-time biomarker monitoring platform that offers molecular patient data. The technology integrates into a wearable smart patch that continuously captures and transmits data to mobile and web-based applications for easy integration with hospital and consumer health software. 

Visit website.

NV Medtech, Inc. was formed based on an exclusive license from EnCompass Technologies, Inc., a cardiovascular company focused on Cerebral Embolic Protection in the TAVR market. NV Medtech is developing a flow diverter with a wire frame and an electrospun cover for the treatment of cerebral (Brain) aneurysms. The NV Medtech TUBE (Total Unilaminar BridgE) Flow Diversion Platform will compete with current metal wire frame Flow Diverters. With an electrospun membrane, the TUBE Flow Diverter has the ability to deploy simply like a stent, but provide double the surface coverage and significantly higher pore density than available flow diverters. Utilizing different materials than we have seen in cerebral flow diversion, TUBE has an ultra thin polyeurethane layer bound with a unique surface modification to ensure that there is a reduced risk to local side branches or thrombosis. Unlike any other available flow diverter, the elctrospun membrane is penetrable, allowing physicians to proceed with confidence as they maintain all of their options for retreatment if necessary.

Nyxoah is a medical technology company developing innovative neuromodulation therapies for obstructive sleep apnea (OSA). Its lead product, Genio, is a battery-free, minimally invasive hypoglossal nerve stimulation device implanted through a single incision and controlled by a wearable. Designed as an alternative to CPAP therapy, Genio has demonstrated best-in-class outcomes for reducing OSA burden. Nyxoah aims to transform sleep health for the over one billion people affected by OSA worldwide.

Visit website.

O2matic is a Danish medtech innovator delivering autonomous oxygen therapy systems that automatically monitor and adjust oxygen flow for patients. Its certified, clinically proven technology reduces hospital costs, improves patient outcomes, and enables scalable home treatment solutions. Positioned at the intersection of digital health and respiratory care, O2matic addresses a global market with strong growth potential and recurring revenue opportunities.

Visit website.

OK2Predict unlocks predictive fall-risk insights from existing wearable data—without new hardware or workflow disruption.

OLI is a medical device company developing a platform for accessible, affordable kidney care.  The company is building compact, low-cost systems to unlock clinical-quality hemodialysis and hemodiafiltration therapies for kidney failure patients from virtually anywhere.

Visit website.

Opsin Biotherapeutics is developing a novel, non-opioid approach to treating chronic pain through optogenetic neuromodulation. The company’s technology uses laser gene delivery to introduce light-sensitive opsins into spinal neurons that naturally block pain signals. Once transformed into photoreceptors, these neurons are activated by low-power red light, providing targeted pain relief without drugs or traditional spinal cord stimulation. Opsin’s platform has the potential to redefine chronic pain management by offering a precise, durable, and side-effect-free alternative to existing therapies.

Visit website.

OptimalPSI developed a proprietary biomechanical optimization algorithm (patent pending) to design patient-specific spinal fusion implants aimed at reducing the risk of subsidence for osteoporotic patients, a major post-operative complication.

Visit website.

Osheru has developed innovative technology using compression skin contouring to remove excess unwanted skin. Our first product, the Ziplyft, makes an eyelid lift minimally invasive and easier on the surgeon and the patient, increasing efficiency by eliminating the need for cautery and suturing. With Ziplyft, surgeons can offer a premium experience to their patients and patients benefit with a natural refreshed look with improved symmetry, reduced downtime, and faster recovery than traditional blepharoplasty. At Osheru we are ‘Opening Eyes Beautifully'.

Visit website.

PreSize Neurovascular is an AI-powered medical device software that enables surgeons to accurately plan and rehearse procedures for the minimally invasive treatment of brain aneurysms with implantable devices. PreSize Neurovascular simulates how a vast digital library of commercially available implants behave in a patient’s anatomy with unprecedented realism, achieving an accuracy of >95% consistently. That way the surgeon can select the optimal implant for every patient, first time around.

Visit website.

Peerbridge Health develops remote cardiac monitoring technologies designed to improve diagnostic accuracy and patient comfort. Its flagship product, the Peerbridge Cor System, is a compact, multi-channel wireless ECG device with the smallest on-body footprint of any wearable ECG. 

Visit website.

Percy is a paradigm-shifting contactless, non-video, multi-sensor behavioral sleep monitoring device with thermal, radar, microphones, and environmental sensors and an AI algorithm that intuits behavioral insights in real time. Doctors access a database where they can access a timeline with objective baseline data to identify episodic problematic events that disrupt sleep, discriminate between medical and behavioral sleep challenges, and monitor treatment compliance without patient report.

Visit website.

The OtoSight Middle Ear Scope enables clinicians to quickly and easily see directly through the eardrum to directly visualize the middle ear, drastically improving care for middle ear infections, the leading cause of hearing loss, antibiotic use, and surgeries in children. The novel device has new reimbursement codes that are seeing robust payment rates.

Visit website.

Biologics grow in volume and viscosity, pharma companies are pushing to move therapies from infusion to at-home subcutaneous delivery, exposing the limits of traditional spring-based injectors. Portal Instruments is developing software-defined, computer-controlled auto-injectors that actively regulate pressure and flow to enable reliable large-volume delivery across viscosities while supporting a broader range of formulations. By capturing real-time injection data, the NEXUS platform can support adherence and therapy management and serve as a cornerstone for future AI-enabled therapies, positioning drug delivery as both a device and data platform.

Preceptis Medical develops technologies that enable pediatric ear tube procedures to be performed in the office without general anesthesia. The Hummingbird® Tympanostomy Tube System (TTS) allows ENTs to place ear tubes efficiently under local anesthesia, eliminating the need for an operating room while maintaining established standards of safety and effectiveness for one of the most common pediatric procedures.

Visit website.

Why not use technology to reduce the risk of chronic use and addiction when prescribing addictive medications, while also saving valuable time for healthcare professionals? Prescriby is a data-driven treatment management platform designed for addictive medications. It provides a safe and efficient solution for health clinics managing and prescribing substances like opioids and benzodiazepines.

Visit website.

Prevencio develops personalized blood tests designed to improve the early detection and prevention of cardiovascular disease. Using machine learning, multi-proteomic biomarkers, and proprietary algorithms, Prevencio’s technology aims to provide more accurate diagnostic and prognostic insights than traditional methods. The company's patented tests have been published in leading cardiology journals and presented at major cardiovascular conferences. Prevencio’s approach is intended to reduce unnecessary procedures and improve patient outcomes.

Visit website.

Pulnovo Medical is developing radiofrequency (RF) solutions for the treatment of pulmonary hypertension. PADN is a multipolar synchronous pulmonary artery RF ablation catheter that is intended to treat pulmonary hypertension by ablating the sympathetic nerve at the target site. The device is capable of point-to-point ablation of pulmonary sympathetic nerves.

Visit website.

Pulsli have created an AI-enabled fluid overload predictor in patients with congestive heart failure. The clinically validated technology provides noninvasive remote patient self-monitoring, improving user engagement and reducing the workload of health professionals.

Visit website.

Purgo Surgical is a medical device company developing novel localized drug delivery technologies designed to enhance therapeutic outcomes while reducing systemic side effects. The company’s platform offers precision, targeted drug delivery across multiple clinical indications.

Visit website.

Rapid Infection Diagnostics Inc. (RID) has developed a rapid ID/AST technology for bloodstream infection and urinary tract infections.

Visit website.

Rekovar develops wearable biosensor technology aimed at improving the management of Neonatal Abstinence Syndrome (NAS). Its flagship product, NeoMonki, is an investigational neonatal monitoring kit designed to provide real-time, objective data on infants' physiological and behavioral states. The system includes a wristband sensor, imaging camera, tablet application, and a provider portal, enabling healthcare professionals to deliver personalized care and intervention.

Visit website.

Restora Medical, Inc. is a medical device company developing the treatment of obstructive sleep apnea (OSA) through advanced neuromodulation technology. Designed for superior performance and expanded patient access, Restora’s innovative solution addresses the limitations of current treatments, providing long-term relief and restoring restful sleep.

Visit website.

Retia develops healthtech AI algorithms for helping guide management of surgical and critically ill patients to improve outcomes. This is a $4 billion market. The company's technology has been clinically validated and is used in 65 hospitals. 

Visit website.

ReVision Implant is developing a cortical visual prosthesis designed to restore functional vision in individuals who are blind. The company’s implant features thousands of microelectrodes that, together with advanced stimulation algorithms, directly transmit visual information from a video feed to the brain’s visual cortex, bypassing damaged optical pathways.

Visit website.

Rheoxtech is developing Rheox™, a catheter-based reperfusion system designed to mitigate cardiac damage that occurs when blood flow is restored after acute myocardial infarction. The system delivers controlled, gradual reoxygenation at the moment of reflow without disrupting standard door-to-balloon workflow. Early clinical and translational data suggest meaningful reductions in infarct size and biomarkers of injury, supporting its potential to improve outcomes for high-risk STEMI patients.

Visit website.

RIVANNA develops AI-enabled ultrasound imaging platforms for applications in neuraxial anesthesia and emergency fracture assessment. Its Accuro 3S system provides real-time, automated epidural and spinal guidance, while Accuro XV leverages AI-driven 3D imaging for radiation-free fracture detection in emergency and mass-casualty settings.

Visit website.

Robeauté is developing a microrobot for novel therapies in hard-to-reach areas of the body. Designed specifically for the brain, at the service of neurosurgeons, the company’s microrobot will be able to freely navigate in other complex regions of the body to perform biopsies, collect precise anatomically localized data and deliver therapies on site, at the right dosage. 

Visit website.

Robossis is developing the first surgical robotic platform specifically designed for long-bone fractures. The patented parallel robotic system, integrated with optical navigation, precisely aligns and stabilizes fractured bone segments intra-operatively. This technology addresses high malalignment and reoperation rates in orthopedic trauma, aiming to improve outcomes while reducing operative time, radiation exposure, and overall cost of care.

Visit website.

SamanTree Medical's Histolog Scanner is a digital microscopy scanner for high-resolution imaging of the surface of fresh tissue. The device utilizes novel, ultra-fast confocal microscopy technology to enable rapid histological assessment in the operating room or pathology laboratory. 

Visit website.

Scalpel AI builds a connected surgical intelligence platform with AI-driven systems for the surgical supply chain and sterile services, focusing on instrument recognition, tray validation, and workflow automation. Their technology helps hospitals, orthopedic and spine device companies, distributors, and sterile processing divisions to reduce errors, streamline logistics, and improve instrument readiness.

Visit website.

Scout Health is bringing rapid molecular testing to the point-of-care. The Scout System packages similar technology to PCR lab-grade tests that normally require a clinic to be performed into a small hub and single-use tests. The system is currently approved for the testing of COVID, with additional tests for common illnesses in development. 

Visit website.

Seattle Neurosound Solutions (SNS) is a pre-seed medical technology company developing a breakthrough wearable transcranial ultrasound platform called The TCD Patch™ for noninvasive ultrasound monitoring and therapeutic intervention to enhance cerebral blood flow (CBF)  oscillations known as intracranial B waves which track the driving force for glymphatic flow in the brain.  Applications also span acute stroke therapy, stroke prevention, cognitive decline prevention via glymphatic flow enhancement, and real time neuromodulation.

Visit website.

Serox is an Oxford-based company developing a low-cost, non-invasive point-of-care in vitro diagnostic that uses urine and a combination of photonics, quantum sensing, and AI to identify cancer at the point of need. The platform leverages Surface Enhanced Raman Spectroscopy (SERS) with a disposable cartridge and desktop analyser to deliver results in under three minutes, and initial validation efforts focus on bladder and prostate cancer with plans to bundle related tests and UTI speciation. By replacing chemistry-based assays with photonics and machine learning, Serox aims to personalize urinalysis and reduce unnecessary invasive procedures such as cystoscopy and prostate biopsy.

Visit website.

SkylineDx is a commercial-stage diagnostic company focused on research and development
of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx
uses its expertise to bridge the gap between academically discovered gene expression
signatures and commercially available diagnostic products with high clinical utility. Based on
tests results, healthcare professionals can accurately assess patient recurrence risk and
tailor the treatment approach to the individual patient. Headquartered in Rotterdam, the
Netherlands, SkylineDx maintains a strong U.S. presence with a CAP/CLIA certified
laboratory in San Diego and a nationwide commercial sales and service organization that
ensures full operational support and market penetration across the U.S. market.

Visit website.

SmartAlpha is focused on leveraging AI to remove the skill barrier that limits the
adoption of ultrasound imaging. Our real-time AI solutions transform standard grayscale ultrasound
imaging into intuitive, anatomy-aware imaging to support ultrasound-based procedure guidance and
diagnostic imaging. Nerveblox AI, now commercially available in 34 countries simplifies ultrasound image
guidance for performing twelve most commonly used nerve blocks in the peri-operative setting.

Visit website.

Solaris Endovascular, Inc. is a growth stage, US-based medical device company developing advanced endovascular solutions for patients suffering from dialysis access challenges and Peripheral Artery Disease. With a proven stent platform and innovative drug-eluting technology, led by seasoned executives with extensive experience in cardiovascular MedTech, Solaris Endovascular is uniquely positioned and committed to improving long-term patient outcomes and transforming vascular health.

Visit website.

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants.

Visit website.

The Somavac system is designed to apply deep tissue Negative Pressure Therapy to reduce and prevent the occurrence of seroma in patients who have recently undergone breast reconstruction and mastectomies. Somavac is intended to reduce post-operative complications and the time requiring surgical drains following surgery. The system is self-contained within a belt to discretely remove fluid and prevent build-up that can lead to complications. 

Visit website.

Sovato is creating access to high-quality care by enabling and orchestrating safe, scalable, and profitable remote robotic surgery and procedure programs that span the entire surgical journey. Sovato is the world’s first and only robot-agnostic platform enabling remote programs for healthcare organizations at a global scale. 

Visit website.

Spinally is developing an intrathecal spinal cord stimulation and recording system that significantly improves on existing neuromodulation solutions. Unlike conventional products, Spinally’s technology offers superior spatial precision and deeper stimulation capabilities while consuming less power. It also enables high-fidelity neuronal signal recording, supporting closed-loop approach. The device is designed for rapid deployment using a micro-needle insertion method, which simplifies the surgical process and minimizes patient recovery time. Our initial focus is chronic pain. However, the system's design and performance open opportunities across a broader range of therapeutic applications: Parkinson’s disease, neurorehabilitation, and spine-computer interface, creating a path toward treating complex neurological conditions with greater specificity and adaptability.

Visit website.

Spiro Robotics is developing an innovative handheld robot intended to automate airway management in patients requiring tracheal intubation. 

Visit website.

StimAire's patented technology is an injectable, rice-grain sized neurostimulator (combined with a small wearable) for treating Obstructive Sleep Apnea, a $30B market. Replacing major surgery with a 15-minute injection is expected to lead to worldwide reimbursement and full market acceptance. This technology has shown feasibility and safety in humans in 2023, has shown repeatability and chronic performance in animals in 2025, and was awarded FDA Breakthrough Device Designation in 2024. 

Visit website.

Stimdia is addressing a major unmet need in critical care by using phrenic nerve neuromodulation to improve breathing in mechanically ventilated patients. By activating the diaphragm through its native neural pathway, Stimdia’s technology has the potential to shorten time on ventilation and improve patient outcomes in the ICU.

Visit website.

Symphera is the first surgical system designed to keep procedures in continuous flow, replacing manual instrument switching with a multi-instrument system. It supports both traditional laparoscopic and robotic surgery, reducing complexity and workflow interruptions in the OR.

Visit website.

SynchNeuro is developing a non-invasive, brain-based continuous glucose monitoring system that tracks blood glucose via analysis of neural signals. The company’s discreet sensor, worn behind the ear, also captures sleep quality and other physiological metrics to support ongoing health management. By offering a pain-free alternative to traditional glucose monitoring, SynchNeuro aims to improve convenience and adherence for people who need regular metabolic monitoring.

Visit website.

Opis is a next‑generation, collagen‑based embolic material engineered for transcatheter embolization and occlusion procedures. It delivers meaningful advantages over coils, plugs, liquid embolics, and microspheres, offering >20× volumetric expansion, complete bioresorption, and smooth, catheter‑based deployment with ease of use. The company plans to submit a 510(k) application to the FDA by the end of 2026, with first‑in‑human studies expected to begin later this year.

Visit website.

Tempo Therapeutics is a San Diego-based biotechnology company advancing tissue engineering through its proprietary MAP (Microporous Annealed Particle) material science technology. The platform enables the in vivo formation of functional tissue and organs and supports the development of next-generation vaccines that are shelf-stable and multivalent. MAP scaffolds are fully synthetic, minimally invasive, and designed to evade immune rejection while promoting a pro-regenerative immune response. Tempo’s mission is to use MAP to help define the future of medicine.

Visit website.

Tensor Surgical develops technologies for orthopedic soft tissue repair sports medicine. The company’s portfolio of products consists of solutions to simplify and reduce the cost rotator cuff repair and bicep tenodesis procedures. 

Visit website.

THINK Surgical develops and commercializes robotic surgery systems for the orthopedics market. The company's TSolution One is indicated for total knee arthroplasty. The system is capable of fully automated bone preparation that is personalized and prepared utilizing proprietary planning tools to achieve optimal fit of the selected knee implant.

Visit website.

Trace Biosciences is a biotechnology company developing fluorescent imaging agents to help surgeons visualize and preserve nerves during surgery. The company’s proprietary molecule selectively labels nerve fibers, enabling real-time identification and reducing the risk of surgical nerve injury—a complication affecting over 25 million patients each year. By integrating fluorescence-guided visualization into standard surgical workflows, Trace Biosciences aims to eliminate preventable nerve damage and transform surgical safety.

Visit website.

TrackX is an instrument tracking technology designed for fluoroscopically-guided medical procedures.  As an intraoperative tool, TrackX has been shown to decrease radiation exposure to everyone in the OR up to 90% and make surgery more accurate all while decreasing time of surgery substantially.  With that, TrackX has become the predominant enabling technology to several of the most common spine surgeries in the US.

Visit website.

Cultivating brain health therapy through continuous, ultra-long-term EEG monitoring and transformative real-world data. Our MDR CE-approved 24/7 EEG SubQ solution captures subcutaneous brain activity to deliver actionable insights that empower clinicians and researchers to personalize treatment and reduce uncontrolled seizures in epilepsy. By harnessing AI and big data, we are unlocking new possibilities in digital biomarkers, drug development, and neuromodulation.

Visit website.

URO-1is an emerging medtech company developing proprietary surgical solutions for office-based urology. The company is targeting the challenges associated with inadequate biopsy, which can lead to increased costs, procedure duplication, and diagnostic delay. The SUREcore and coreCARE platforms are two solutions within the company’s portfolio that are intended to improve the standard of care in prostate biopsy and other soft tissue biopsy procedures.

Visit website.

Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency.

Visit website.

Vena Vitals is an early stage med-tech company focused on non-invasive continuous blood pressure monitoring. The company's proprietary technology is a soft flexible sensor that conforms to the skin for direct pressure measurement at theradial artery. The company's technology is intended to replace unnecessarily invasive arterial line measurements as well as non-continuous cuff-based methods in both the hospital and at home.

Visit website.

Vergent’s lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows.

Visit website.

Veris Health Inc., is a digital health company whose lead product is a digital cancer care platform with physiologic data collection, symptom reporting and telehealth functions, designed to improve personalized cancer care through remote patient monitoring. Veris has also been developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris cancer care platform.

Visit website.

Versono is developing an intravascular ultrasonic platform to improve the crossing of severe occlusions in the peripheral vasculature. The device will prepare a working lumen to support endovascular therapy in patients with chronic total occlusions (CTOs) and critical limb ischemia (CLI).

Visit website.

VirtaMed develops mixed-reality surgical simulators designed to enhance medical education and improve patient outcomes. Its platforms integrate real surgical instruments with haptic feedback and photorealistic graphics to provide immersive training experiences across specialties such as orthopedics, obstetrics and gynecology, urology, and general surgery. VirtaMed also offers customizable training solutions for medical device companies and educational institutions, supported by its cloud-based platform, VirtaMed Connect, for performance tracking and curriculum development. The company is headquartered in Zurich, Switzerland, with additional locations in the United States and China.

Visit website.

Description coming soon.

Visit website.

Wearable Artificial Organs is developing truly portable solutions for use in patients with End Stage Renal Disease (ESRD). The company has currently prototyped two wearable device, a cordless continuous renal replacement therapy (CRRT) system and a wearable artificial kidney. 

Visit website.

XEOS is committed to improving surgical outcomes using intraoperative imaging. Our flagship product, the AURA 10 PET-CT, is the world’s first specimen PET-CT imager. It provides surgeons with the ability to see wat they can’t see with the naked eye: a 3-dimensional molecular map of the resected specimen - providing the ability to instantly assess if surgery achieved its goal.

Visit website.

Millions of people in the U.S. suffer from degenerative arthritis of their knees. At least 20% of these patients have arthritis localized to their patellofemoral joint ( knee cap) with an addressable market of $2 Billion. Until now the only available options have been highly invasive surgeries, including knee replacement. The ZKR Patella LIFT implant offers patients a minimally invasive alternative to knee replacement at a significantly lower cost and a much faster recovery.

Visit website.